DR. STEVEN BRADLEY HARRIS, M.D.
Osteopathic Medicine at Civic Center Dr, Rancho Cucamonga, CA
License number
California G52760
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California 310666-1205
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
10743 Civic Center Dr, Rancho Cucamonga, CA 91730
Phone
(909) 987-3883
(909) 987-7253 (Fax)
(909) 987-7253 (Fax)
Personal information
See more information about STEVEN BRADLEY HARRIS at radaris.comName
Address
Phone
4756 Kensington Dr, San Diego, CA 92116
4777 E Butler Ave, Fresno, CA 93702
4700 Natick Ave UNIT 307, Sherman Oaks, CA 91403
4812 Santa Monica Ave, San Diego, CA 92107
4993 W Olympic Ave, Banning, CA 92220
Professional information
Dr. Steven B Harris, Rancho Cucamonga CA - MD (Doctor of Medicine)
Specialties:
Geriatric Medicine
Address:
10743 Civic Center Dr, Rancho Cucamonga 91730
(909) 987-3883 (Phone), (909) 987-7253 (Fax)
(909) 987-3883 (Phone), (909) 987-7253 (Fax)
Languages:
English
Education:
Medical School
University of Utah
Graduated: 1983
University of Utah
Graduated: 1983
Steven Bradley Harris, Rancho Cucamonga CA
Specialties:
Internal Medicine
Work:
Critical Care Research
10743 Civic Center Dr, Rancho Cucamonga, CA 91730
10743 Civic Center Dr, Rancho Cucamonga, CA 91730
Education:
University of Utah (1983)
Microemulsion Preparation Of High Concentration Propofol For Anesthetic Uses
US Patent:
2013013, May 23, 2013
Filed:
Jan 11, 2013
Appl. No.:
13/740091
Inventors:
Steven B. Harris - Rancho Cucamonga CA, US
Nick J. Huang - Rancho Cucamonga CA, US
Nick J. Huang - Rancho Cucamonga CA, US
International Classification:
A61K 9/107
US Classification:
514731
Abstract:
The invention provides a method and a composition for enhancing the dissolution and bioavailable properties of propofol (2, 6 diisopropyl phenol) for use as an intravenously administered anesthetic in mammals. The method produces a self-microemulsifyable emulsion base composition that is utilized in the production of a water-based microemulsion preparation. In a preferred two (2) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; and liquid propofol. The microemulsion is prepared by mixing the base composition with a carrier liquid, which results in the formation of a microemulsion containing concentrations of propofol of up to about 4% by weight of propofol to the volume of the microemulsion. In a four (4) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; liquid propofol; a water-immiscible solvent; and ethanol. The microemulsion is prepared by mixing the base composition with a carrier liquid, which results in the formation of a microemulsion containing concentrations of propofol of up to about 10% by weight of propofol to the volume of the microemulsion.